DK1626726T3 - Anvendelse af lornoxicam eller lornoxicam-analoger - Google Patents

Anvendelse af lornoxicam eller lornoxicam-analoger

Info

Publication number
DK1626726T3
DK1626726T3 DK04734972T DK04734972T DK1626726T3 DK 1626726 T3 DK1626726 T3 DK 1626726T3 DK 04734972 T DK04734972 T DK 04734972T DK 04734972 T DK04734972 T DK 04734972T DK 1626726 T3 DK1626726 T3 DK 1626726T3
Authority
DK
Denmark
Prior art keywords
lornoxicam
analogues
oxygenase
cox
cyclo
Prior art date
Application number
DK04734972T
Other languages
English (en)
Inventor
Dieter Di Binder
Original Assignee
Binder Eva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Binder Eva filed Critical Binder Eva
Application granted granted Critical
Publication of DK1626726T3 publication Critical patent/DK1626726T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK04734972T 2003-05-27 2004-05-27 Anvendelse af lornoxicam eller lornoxicam-analoger DK1626726T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0081903A AT413944B (de) 2003-05-27 2003-05-27 Verwendung von oxicam-verbindungen

Publications (1)

Publication Number Publication Date
DK1626726T3 true DK1626726T3 (da) 2006-12-27

Family

ID=33479909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04734972T DK1626726T3 (da) 2003-05-27 2004-05-27 Anvendelse af lornoxicam eller lornoxicam-analoger

Country Status (13)

Country Link
US (2) US8129370B2 (da)
EP (1) EP1626726B1 (da)
JP (1) JP5597339B2 (da)
KR (1) KR101134244B1 (da)
CN (3) CN102218067A (da)
AT (2) AT413944B (da)
CA (1) CA2526816C (da)
DE (1) DE502004001499D1 (da)
DK (1) DK1626726T3 (da)
ES (1) ES2271893T3 (da)
PL (1) PL1626726T3 (da)
RU (1) RU2366425C2 (da)
WO (1) WO2004105766A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005238220A1 (en) * 2004-04-29 2005-11-10 Binder, Eva Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives
CA2742771A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
US9707231B2 (en) 2011-11-01 2017-07-18 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
CN115227655A (zh) * 2022-08-17 2022-10-25 海南锦瑞制药有限公司 注射用氯诺昔康的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
JPS58146040A (ja) * 1982-02-24 1983-08-31 Pioneer Video Kk 光学式情報記録原盤
EP0103142B1 (de) * 1982-09-09 1987-04-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Thieno(2,3-e)-1,2-thiazin-Derivate
NZ226477A (en) * 1987-10-29 1990-07-26 Cl Pharma Substituted thieno (2,3-e)-1,2 thiazine derivatives and pharmaceutical compositions
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
AT400437B (de) * 1993-12-14 1995-12-27 Chem Pharm Forsch Gmbh Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
TWI256305B (en) * 2000-08-18 2006-06-11 Pharmacia Corp Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
JP2002363104A (ja) 2001-04-04 2002-12-18 Sankyo Co Ltd 炎症性サイトカイン産生抑制剤の新規医薬用途
ATE375173T1 (de) * 2001-08-20 2007-10-15 Fujifilm Corp Hydrophobe iodverbindung enthaltendes liposom und dieses enthaltendes röntgenkontrastmittel
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents

Also Published As

Publication number Publication date
KR101134244B1 (ko) 2012-04-09
JP2006528206A (ja) 2006-12-14
RU2005136864A (ru) 2006-06-10
ES2271893T3 (es) 2007-04-16
ATA8192003A (de) 2005-11-15
DE502004001499D1 (de) 2006-10-26
RU2366425C2 (ru) 2009-09-10
WO2004105766A2 (de) 2004-12-09
CA2526816A1 (en) 2004-12-09
PL1626726T3 (pl) 2007-02-28
US20090239852A1 (en) 2009-09-24
KR20060017618A (ko) 2006-02-24
JP5597339B2 (ja) 2014-10-01
WO2004105766A3 (de) 2005-03-03
CN102218067A (zh) 2011-10-19
ATE339206T1 (de) 2006-10-15
AT413944B (de) 2006-07-15
US20070275958A1 (en) 2007-11-29
CN101450057A (zh) 2009-06-10
EP1626726A2 (de) 2006-02-22
US8129370B2 (en) 2012-03-06
CA2526816C (en) 2012-11-27
CN1842338A (zh) 2006-10-04
EP1626726B1 (de) 2006-09-13

Similar Documents

Publication Publication Date Title
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
NO20076405L (no) Anvendelse av 24-nor-UDCA
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE502004011919D1 (de) -trien-3-yl sulfamate
DK1626726T3 (da) Anvendelse af lornoxicam eller lornoxicam-analoger
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
ITRM20000433A0 (it) Uso di fibrati per la preparazione di un medicamento utile nel trattamento dell&#39;insufficenza cardiaca congestizia.
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
DE60216090D1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia